Next Phase Newsletter

A European focused venture capital firm founded in 2015 with partners based in Europe and US is currently actively investing in Spain, Portugal, the UK, and Ireland. The firm is expanding into the Baltics and raising a new €100 million fund. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in series A & series B financings as a Lead or co-Lead with investments ranging from €3 million to €8 million over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over next 4 years. The firm will only invest in private companies.

The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is strongly interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platform and analytics areas, such as big data-driven technologies on complex medical research.

The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in New York has several decades of experience in investing in life science companies and taking them public. The firm participates in deals across all stages of development, from seed to mezzanine funding. In early-stage deals, the firm’s initial check size is usually between $250-500K, with potential for follow-on financing as the companies achieve key growth milestones. The firm is actively involved with a well-established angel investor group and makes investments through this group as well. The firm is open to opportunities all across the globe.

The firm seeks to invest broadly across different silos of the life sciences ecosystem, from therapeutics, devices, diagnostics, and digital health. The firm’s strongest interest and expertise lies in biotech, and many of the firm’s investments have been in therapeutics companies. The firm is also open to companies of all stages of development and is indication agnostic, but has significantly higher standards for oversaturated, competitive spaces such as oncology.

The firm has no explicitly stated company or management team requirements. The firm likes to become actively involved in their portfolio companies and supports them with needed resources and advisory services to help them grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical arm of a large Japanese company with a full-fledged licensing and clinical development office in the USA, is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the pharma company contributing personnel, sharing studies and research tools, or providing research expense funding.

The firm is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: Metabolic / Cardiovascular Diseases (NASH, Heart failure (HFrEF, HFpEF, Hypertrophic cardiomyopathy), Diabetic Retinopathy / Diabetic Macular Edema, Chronic Kidney Disease, Sarcopenia), Autoimmune Diseases (Multiple Sclerosis, Lupus, IBD), CNS disorders (Alzheimer’s Disease, Schizophrenia). As well as drugs, The firm is interested in drug targets in these disease areas.

The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase. For in-licensing for the Japan market, the firm is focused on renal diseases, dermatology and allergic diseases. The firm also invests in drug discovery technologies and research tools such as: technologies related to translational research using cell culture, isolated cellular organelles and related mechanisms; HTS technologies; protein structure analysis; chemical biology, chemical synthesis, and chemical libraries; biophysical tools; in silico technologies; biomarkers and bioinformatics screening, biomarker research, and compound libraries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm and company builder with headquarters in Western Europe and an additional office in USA is allocating their funds primarily into companies in Europe and North America. There is an approximately 50:50 split between traditional equity investments and venture creation, the initial investment size is in the range from $1-5M in the Seed Round and additional $10-15M for subsequent rounds.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm is primarily focused on therapeutics, but is also considering advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, The firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat, but are also open to joining strong syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC fund based in the USA invests in many sectors, including IT, e-commerce, cloud businesses, media & telecommunications, clean technology and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are close to seeking FDA approval. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component or a disposable associated with the device. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have a minimum of $2M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA makes equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States, and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with investment teams in Silicon Valley (headquarters) and Europe is currently investing out of their third $355M fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. the firm is only interested in preclinical/Phase I, early-stage technology. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.